Funder
National Cancer Institute (NCI) to MD Anderson Cancer Center in the form of the SPORE in Multiple Myeloma
Cancer Center Support Grant
Cancer Therapy Evaluation Program (CTEP) grant
Leukemia and Leukemia Society Translational Research Program Award
Multiple Myeloma SPORE
National Cancer Institute
MD Anderson Cancer Center High-Risk Multiple Myeloma Moon Shot
Brock Family Myeloma Research Fund
Yates Ortiz Myeloma Fund
Diane and John Grace Family Foundation
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference38 articles.
1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol Off J Am Soc Clin Oncol 27:2758–2765
2. Kumar SK, Lee JH, Lahuerta JJ et al (2012) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26:149–157
3. Tjin EPM, Derksen PWB, Kataoka H, Spaargaren M, Pals ST (2004) Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator. Blood 104:2172–2175
4. Wader KF, Fagerli UM, Holt RU et al (2008) Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma. Eur J Haematol 81:380–383
5. Derksen PWB, Keehnen RMJ, Evers LM, van Oers MHJ, Spaargaren M, Pals ST (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes met signaling in multiple myeloma. Blood 99:1405–1410